September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
6 weeks PRN intravitreal treatments results for macular diseases. One year clinical practice data.
Author Affiliations & Notes
  • Marcos Javier Rubio Caso
    Hospital Universitari de Bellvitge, Sant Boi de Llobregat - Barcelona, Spain
  • Rahul Morwani Morwani
    Hospital Universitari de Bellvitge, Sant Boi de Llobregat - Barcelona, Spain
  • Carla Veiga Sanchez-Tinajero
    Hospital Universitari de Bellvitge, Sant Boi de Llobregat - Barcelona, Spain
  • Luis Arias Barquet
    Hospital Universitari de Bellvitge, Sant Boi de Llobregat - Barcelona, Spain
  • Josep Maria Caminal Mitjana
    Hospital Universitari de Bellvitge, Sant Boi de Llobregat - Barcelona, Spain
  • Footnotes
    Commercial Relationships   Marcos Rubio Caso, Bayer (R), Novartis (R); Rahul Morwani Morwani, None; Carla Veiga Sanchez-Tinajero, None; Luis Arias Barquet, Bayer (R), Novartis (R); Josep Maria Caminal Mitjana, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 3370. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Marcos Javier Rubio Caso, Rahul Morwani Morwani, Carla Veiga Sanchez-Tinajero, Luis Arias Barquet, Josep Maria Caminal Mitjana; 6 weeks PRN intravitreal treatments results for macular diseases. One year clinical practice data.. Invest. Ophthalmol. Vis. Sci. 2016;57(12):3370.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : PRN (Pro Re Nata) monthly treatment is the preferred treatment modality for most of the studies involving antiVGEF drugs. However, results obtained in actual clinical practice are lower that predicted due to the burden of monthly visits and injections. A 6 weeks PRN regimen can improve the accompliment of patients while maintaining the benefits of treatment.

Methods : Retrospective analysis of all patients treated with intravitreal injections from May 2014 to May 2015. Eyes with 6 or more visits and completed loading dose were selected for analysis.. Disease activity were monitorized with SD-OCT in all visits. Intravitreal injection were delivered in the same visit if needed. Group analysis were based on disease (AMD, DME and Vein occlusion) recording number of annual visits and injections. Visual acuity benefit was calculated for each group.

Results : Data from 138 eyes from 127 patients were recorded. Total visits: 820. Total injections: 497. 100 eyes (72%) achieved 6 or more visits during the study period. Total visit average per year: 6.72. Total intravitreal injection averaged per year: 4,20. Total Visual accuity benefit: +0.57. AMD: Visits/year: 6.88. Injections/year: 4.05. VA changes from baseline: -0.33. DME: Visits/year: 6.77. Injections/year: 4.76. VA changes from baseline: +0.71. Vein occlusion: Visits/year: 6.71. Injections/year: 3.71. VA changes from baseline: +3.11. Drug use: Ranibizumab (64%), Aflibercept (27%), Ozurdex (5%), Avastin (4%). Switch of drugs: 18 eyes. Aflibercept: 13 cases. Ranibizumab: 2 cases. Ozurdex: 3 cases.

Conclusions : 6 weeks PRN regimen can achieve a good balance between number of visits and drug efficiency use. Mantaining visual acuity is possible for a large number of patients while reducing the burden of intravitreal treatments.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×